2-氰基-N-异丙基乙酰胺 | 52573-74-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氰基-N-异丙基乙酰胺
• 中文别名: 2-氰基-N-(1-甲基乙基)乙酰胺
• 英文名称: 2-cyano-N-isopropylacetamide
• 英文别名: 2-cyano-N-propan-2-ylacetamide
• CAS: 52573-74-7
• 化学式: C₆H₁₀N₂O
• mdl: MFCD00828755
• 分子量: 126.158
• InChiKey: LOAHXFVORLJMML-UHFFFAOYSA-N

物化性质

• 熔点：
  62 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2-氰基-N-异丙基乙酰胺 700.0 ℃ 、0.01 Pa 条件下， 反应 0.33h， 生成 3-氧代丙烯腈
  参考文献：
  名称：

  氰基乙烯酮和亚氨基丙二烯酮。

  摘要：

  氰基乙烯酮（8）通过闪蒸真空热解（FVT）适当取代的麦德鲁姆酸衍生物（5-[（（烷基氨基）（甲硫基或烷基氨基）亚甲基] -2,2-二甲基-1,3-二恶烷-4）高产率生成，6-二酮）（3e-j），以及氰基乙酸衍生物9e，f，g，j，k，m的FVT。3的主要反应途径是通过烯酮亚胺6和（烷基亚氨基）丙二烯酮7进行的，后者进行逆烯反应至8。次要途径是通过亚氨基酮烯4e，h和氧烯酮5e，h，它们进行逆烯反应。 9.所有中间体均通过Ar矩阵FTIR和串联质谱（碰撞活化MS）进行表征。还报道了用亲核试剂捕获4、5和8。1,3-X的优先级会超过1，酰亚胺基乙烯酮12（X = SMe或NMe（2））中的5-H位移已通过计算得出的激活势垒得到证实。纯的氰基烯酮具有很高的反应活性，在80 K或更低的温度下会发生反应，这归因于低洼的烯酮LUMO的可用性。氰基烯（Ar，14 K）的IR光谱主要受2163（s; C =

  DOI：

  10.1021/jo9701288
• 作为产物：
  描述：

  5-(Bis-isopropylamino-methylene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 600.0 ℃ 、133.32 Pa 条件下， 以66%的产率得到2-氰基-N-异丙基乙酰胺
  参考文献：
  名称：

  Synthesis of .alpha.-cyano carbonyl compounds by flash vacuum thermolysis of (alkylamino)methylene derivatives of Meldrum's acid. Evidence for facile 1,3-shifts of alkylamino and alkylthio groups in imidoylketene intermediates

  摘要：

  The syntheses and flash vacuum thermolyses of 5-[(alkylamino)methylene]-2,2-dimethyl-1,3-dioxane-4,6-diones (Meldrum's acid derivatives) 13a-i are described. Thermolysis of 13a as well as of ethyl 3-(tert-butylamino)acrylate (22) gives a tautomeric mixture of cyanoacetaldehyde (14) and 3-hydroxypropenenitrile (15). Thermolysis of 13b gives iminoacrolein 26 and not cyanoacetone (29). Thermolysis of 13c,d gives S-methyl cyanothioacetate (30), and 13f-h give cyanoacetamides 31 in high yields. 2-Cyanopent-4-enoic acid derivatives 32 are obtained from Meldrum's acids 13e,i. The results are discussed in terms of facile 1,3-shifts of methylthio and alkylamino groups in imidoylketenes, interconverting imidoylketenes and acylketene imines.

  DOI：

  10.1021/jo00003a014

文献信息

• Pharmacologically active compounds, methods for the preparation thereof
  申请人：Orion-yhtyma Oy

  公开号：US04963590A1

  公开（公告）日：1990-10-16

  Pharmacologically active catechol derivatives of formula I ##STR1## wherein R.sub.1 and R.sub.2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R.sub.3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from ##STR2## wherein R.sub.4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R.sub.5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R.sub.4 and R.sub.5 together form a five to seven membered substituted cycloalkanone ring; --(CO).sub.n (CH.sub.2).sub.m --COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; ##STR3## wherein R.sub.8 and R.sub.9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; --NH--CO--R.sub.10 wherein R.sub.10 comprises a substituted alkyl group.

  公式I的药理活性儿茶酚衍生物，其中R.sub.1和R.sub.2独立地包括氢、烷基、酰基、可选择地取代的芳酰基、较低的烷基磺酰基或烷基氨基甲酰基，或者一起形成较低的烷基亚甲基或环烷基亚甲基，X包括电负取代基，如卤素、硝基、氰基、较低的烷基磺酰基、磺胺基、醛基、羧基或三氟甲基，R.sub.3包括氢、卤素、羟基烷基、氨基、硝基、氰基、三
• Enols of Substituted Cyanomalonamides
  作者：Ahmad Basheer、Hiroshi Yamataka、Salai Cheettu Ammal、Zvi Rappoport

  DOI：10.1021/jo070877h

  日期：2007.7.1

  for E and Z isomeric enols. The equilibrium (KEnol) values between the amides and the enols were determined in different solvents by NMR spectra. They decrease on increasing the polarity of the solvent in the order CDCl3 ∼ C6D6 > THF-d8 > (CD3)2CO > CD3CN > DMF-d7 > DMSO-d6. For the R1R2NCOCH(CN)CONHR3 system when R1 = R2 = H, Me or R1 = H, R2 = Me, KEnol for R3 follows the order: C6F5 > Ph ≥ An ≥ i-Pr

  制备了二十个开链的单，二和三烷基和芳基-N-取代的氰基马来酰胺R 2 R 1 NCOCH（CN）CONHR 3。在溶液中，尽管有E和Z异构烯醇的潜力，但大多数情况下都能观察到酰胺和单个烯醇的信号。通过NMR光谱在不同溶剂中确定酰胺和烯醇之间的平衡（K Enol）值。它们降低上增加溶剂的极性的顺序CDCL 3〜C ^ 6 d 6 > THF- d 8 >（CD 3）2 CO> CD 3CN> DMF- d 7 > DMSO- d 6。对于R 1 R 2 NCOCH（CN）CONHR 3系统，当R 1 = R 2 = H，Me或R 1 = H，R 2 = Me时，R 3的K Enol遵循以下顺序：C 6 F 5 > Ph≥一个≥我-Pr≥吨-Bu，和对于R 1，R 2：H，H>箱，H>我中，Me在所有的溶剂。当R 1 = R 2时，DMSO- d 6中的烯醇百分含量非常高= H，与带有其他吸电
• Enantioselective Cyclopropenation of Alkynes with Acceptor/Acceptor-Substituted Diazo Reagents via Co(II)-Based Metalloradical Catalysis
  作者：Xin Cui、Xue Xu、Hongjian Lu、Shifa Zhu、Lukasz Wojtas、X. Peter Zhang*

  DOI：10.1021/ja111334j

  日期：2011.3.16

  The cobalt(II) complex of a new D(2)-symmetric chiral porphyrin 3,5-diMes-ChenPhyrin, [Co(P2)], has been shown to be a highly effective chiral metalloradical catalyst for enantioselective cyclopropenation of alkynes with acceptor/acceptor-substituted diazo reagents, such as α-cyanodiazoacetamides and α-cyanodiazoacetates. The [Co(P2)]-mediated metalloradical cyclopropenation is suitable to a wide range

  新的 D(2)-对称手性卟啉 3,5-diMes-ChenPhyrin [Co(P2)] 的钴 (II) 配合物已被证明是一种高效的手性金属基催化剂，用于炔烃与受体的对映选择性环丙烯化/受体取代的重氮试剂，例如α-氰基重氮乙酰胺和α-氰基重氮乙酸盐。[Co(P2)] 介导的金属基环丙烯化反应适用于各种具有不同空间和电子性质的末端芳烃和相关共轭炔烃，以高产率提供相应的三取代环丙烯，对全碳四元立体中心具有出色的对映控制. 除了温和的反应条件外，用于环丙烯化的 Co(II) 基金属基催化还具有高度的官能团耐受性。
• KINASE INHIBITORS
  申请人：Taunton, JR. John William

  公开号：US20130035325A1

  公开（公告）日：2013-02-07

  Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.

  使用具有烯烃基团的激酶抑制剂抑制激酶的方法被披露。
• [EN] NOVEL ARGINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS D'ARGINASE
  申请人：UNIV GRONINGEN

  公开号：WO2020249821A1

  公开（公告）日：2020-12-17

  The present invention relates to novel arginase inhibitors of formula (I). These novel compounds are useful in the treatment of diseases that are associated with arginase activity, such as asthma, allergic rhinitis and COPD (chronic obstructive pulmonary disease).

  本发明涉及式(I)的新型精氨酸酶抑制剂。这些新型化合物在治疗与精氨酸酶活性相关的疾病方面具有用途，如哮喘、过敏性鼻炎和慢性阻塞性肺疾病（COPD）。